Compare Gigacloud Technology Inc (GCT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs GeneDx Holdings Corp — how do they compare? Gigacloud Technology Inc trades at $57.26 (market cap $2.02B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Gigacloud Technology Inc and GeneDx Holdings Corp are close in size by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and GeneDx Holdings Corp for 19 Days on average.
| GCT | WGS | |
|---|---|---|
Market Cap | $2.02B | $2.02B |
Volume | 1,020,985 | 734,640 |
Sector | Technology | Health |
52-Week High | $56.42 | $167.51 |
52-Week Low | $25.46 | $34.51 |
Typical Hold Time | 21 Days | 19 Days |
Enterprise Value | $2.14B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $56.42, up 0.82% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust fundamentals with consistent earnings beats, 10.65% net margins, and 32.34% ROE. Revenue growth from $1.29B to $1.5B projected for 2026 supports valuation at 13.44 P/E. Recent news highlights institutional interest and European expansion driving optimism.
Outlook remains positive given earnings momentum and reasonable valuation, though risks include insider selling and competitive pressures. Analyst consensus favors Buy with $32.50 target, but current price exceeds consensus suggesting cautious near-term positioning may be warranted despite strong operational performance.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
